|
市場調査レポート
商品コード
1519455
リキッドバイオプシー市場レポート：製品・サービス、循環バイオマーカー、がんタイプ、エンドユーザー、地域別、2024年～2032年Liquid Biopsy Market Report by Product And Service, Circulating Biomarker, Cancer Type, End User, and Region 2024-2032 |
||||||
カスタマイズ可能
|
|||||||
| リキッドバイオプシー市場レポート：製品・サービス、循環バイオマーカー、がんタイプ、エンドユーザー、地域別、2024年～2032年 |
|
出版日: 2024年07月01日
発行: IMARC
ページ情報: 英文 140 Pages
納期: 2～3営業日
|
- 全表示
- 概要
- 図表
- 目次
世界のリキッドバイオプシー市場規模は2023年に20億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに65億米ドルに達し、2024年から2032年の間に13.5％の成長率（CAGR）を示すと予測しています。がん罹患率の増加、個別化医療と治療に対する需要の高まり、自動化リキッドバイオプシー・プラットフォームの開発は、リキッドバイオプシー市場の成長を促進する主な要因のいくつかです。
リキッドバイオプシー市場分析：
主な市場促進要因次世代シーケンシングのイントロダクションとともに、特に社会人のライフスタイルパターンの変化に起因するがんの有病率の上昇が市場成長を促進しています。リキッドバイオプシーは、血液や尿などの体液中の循環腫瘍細胞（CTC）、無細胞DNA（cfDNA）、エクソソーム等のがん関連バイオマーカーの検出を可能にします。早期発見は、効果的な治療と患者の転帰の改善に不可欠であり、市場成長の原動力となっています。
主な市場動向：技術の進歩、臨床応用の拡大、多分析アプローチへのシフト、早期発見とスクリーニングへの注目の高まり、臨床試験におけるリキッドバイオプシーの採用の高まりなどは、今後数年間の市場成長を刺激すると予想される主要因の一部です。さらに、シーケンス技術、マイクロ流体工学、バイオインフォマティクスにおける継続的な技術革新が、リキッドバイオプシーアッセイの感度、特異性、拡張性を高め、リキッドバイオプシー市場の収益をさらに強化しています。
地域情勢別：報告書によると、北米が最大の市場シェアを占めています。北米ではがんは依然として健康上の大きな関心事であり、人口のかなりの部分が毎年さまざまな種類のがんと診断されています。罹患率の高さが、がんの検出とモニタリングに非侵襲的で正確な方法を提供するリキッドバイオプシーのような革新的な診断ツールに対する需要を促進しています。これはさらにリキッドバイオプシー市場の需要にプラスの影響を与えています。
競合情勢：リキッドバイオプシー市場の主要企業としては、ANGLE plc、Biocept Inc.、Bio-Rad Laboratories Inc.、Epigenomics AG、Exact Sciences Corporation、F. Hoffmann-La Roche AG、Guardant Health Inc.、Illumina Inc.、MDxHealth SA、Menarini Silicon Biosystems、QIAGEN N.V.、Thermo Fisher Scientific Inc.などが挙げられます。
課題と機会：アッセイの標準化とバリデーション、臨床的バリデーションとエビデンスの作成、コストの検討と償還は、現在市場が直面している主要課題の一部です。しかし、リキッドバイオプシーは、人工知能（AI）や機械学習などのデジタルヘルス技術と統合することで、データ分析、解釈、臨床的意思決定を強化することができます。これはメーカーにとって重要な機会です。
リキッドバイオプシー市場傾向：
がんの有病率の上昇
がんの罹患率は世界的に上昇傾向にあり、早期発見とモニタリングが重視されるようになっています。例えば、WHOによると、2022年に新たにがんと診断される人は2,000万人、死亡する人は970万人と予想されています。また、がんと診断されてから5年後に生存している人の数は5,350万人と予想されています。がんは生涯で約5人に1人が罹患します。2050年には3,500万人以上のがん患者が増えると予想され、2022年の推定2,000万人よりも77％増加します。リキッドバイオプシーは、血液や尿などの体液中の循環腫瘍細胞（CTC）や無細胞DNA（cfDNA）などの循環腫瘍バイオマーカーを検出する非侵襲的な方法です。これらのバイオマーカーは、がんの存在、進行、遺伝的プロファイルに関する貴重な洞察を提供し、臨床医がより早い段階でがんを診断し、より効果的に病気の進行を監視することを可能にします。例えば、2023年米国がん学会年次総会において、研究者らは革新的なプラットフォームを使ってDNAメチル化を分析するリキッドバイオプシー多がん早期発見検査に関する報告を行った。従来の検査では塩基配列を決定する前にDNAの化学的治療が必要であったが、この新規アプローチでは化学的・酵素的治療を行うことなくメチル化されたcfDNA分子を捕らえることができます。治療歴のない最近診断されたがん患者と、年齢と性別をマッチさせた対照者を含む約4000人のサンプルにおいて、このプラットフォームが12種類のがんを検出する能力を検証するためにレトロスペクティブ分析が行われました。がん症例の約半数は初期段階でした。さらに2020年には、ペンシルバニア大学の研究チームが、彼らのリキッドバイオプシーが早期膵臓がんの診断において92％の精度を示したことを示す論文を『Clinical Cancer Research』誌に発表しました。これらの要因は、リキッドバイオプシー市場予測にさらにプラスの影響を与えています。
非侵襲的出生前検査（NIPT）の需要増加
羊水穿刺や絨毛膜絨毛採取（CVS）といった従来の出生前検査法には、流産を含む合併症のリスクが少なからずあります。NIPTは、母親の血液中を循環する無細胞胎児DNA（cffDNA）を分析するもので、出生前スクリーニングに非侵襲的な代替手段を提供します。例えば、国立医学図書館によれば、羊水穿刺は妊娠15週から出産までどこでも実施可能であり、専門家の手による一重子の流産確率は0.13％です。これに伴い、妊娠15週以降に羊水穿刺を受けるリスクは100人に1人と推定されています。この非侵襲的なアプローチは、その安全性と処置に関連した合併症のリスクの低減により、多くの妊婦の親に好まれています。さらに、NIPTは、21トリソミー（ダウン症候群）、18トリソミー（エドワーズ症候群）、13トリソミー（パタウ症候群）などの一般的な胎児の染色体異常の検出において高い精度を示しています。また、リキッドバイオプシーに基づくNIPTアッセイは、胎児の遺伝子異常を高い感度と特異度で検出することができ、妊婦の両親に赤ちゃんの健康状態に関する信頼できる情報を提供することができます。例えば、2023年11月、Novacyt社の子会社であるYourgene Health社はLaboriad社と提携し、モロッコ初の非侵襲的出生前検査（NIPT）プラットフォームを導入しました。このほか、NIPTは妊娠9～10週という早い段階で実施できるため、胎児の遺伝的健康について早期に知ることができます。染色体異常の早期発見により、妊婦の両親は妊娠について十分な情報を得た上で決断を下し、追加の診断検査や特別なニーズを持つ子供の出産準備を検討することができます。さらに、NIPTは妊娠9～10週という早い時期に実施することができ、胎児の遺伝的健康について早期に洞察することができます。染色体異常を早期に発見することで、妊婦の両親は妊娠について十分な情報を得た上で決断を下し、追加の診断検査や特別な支援を必要とする子供の出産準備を検討することができます。例えば、クリーブランド・クリニックが発表した記事によると、NIPT検査は早ければ妊娠10週目から出産まで実施できます。これらの要因は、リキッドバイオプシー市場の最近の価格にさらにプラスの影響を与えています。
研究開発活動と臨床試験の増加
リキッドバイオプシーの技術的進歩の高まりは、がんスクリーニング、治験の最適化、治療法の選択の頻度を高めています。様々な政府機関や企業が、リキッドバイオプシーに関する臨床研究を実施するための研究開発投資に注力しています。例えば、2023年6月、Anzu PartnersはCodetta Biosciencesに対して1,500万米ドルのシリーズA投資ラウンドを主導しました。ジェノヴァ・ベンチャーズとVC23 LLCもこの資金調達に貢献しました。この資金調達により、コデッタ社は研究開発、エンジニアリング、マーケティング、経営管理部門のチームを急速に拡大し、リキッドバイオプシー用マルチオミックdsPCRプラットフォームの開発を急ぐ計画です。さらに、臨床試験は、新規のリキッドバイオプシー技術やプラットフォームの性能を評価するためのプラットフォームとして機能します。研究開発への投資により、次世代シークエンシング（NGS）プラットフォーム、デジタルPCRシステム、およびリキッドバイオプシーアッセイの感度、特異性、拡張性を高めるその他の革新的技術の開発が可能になります。臨床試験は、実臨床環境においてこれらの進歩を検証する機会を提供し、商業化と普及への道を開く。例えば、2024年4月には、遺伝子治療製造のギャップに対処することに焦点を当てた技術革新企業であるNewBiologix SAが、バイオ医薬品業界に包括的なゲノム解析サービスを提供する新しい技術群である次世代シーケンシング（NGS）と光マッピングプラットフォームを発表しました。これらの要因がリキッドバイオプシー市場のシェアをさらに押し上げています。
目次
第1章 序文
第2章 調査範囲と調査手法
- 調査の目的
- ステークホルダー
- データソース
- 一次情報
- 二次情報
- 市場推定
- ボトムアップアプローチ
- トップダウンアプローチ
- 調査手法
第3章 エグゼクティブサマリー
第4章 イントロダクション
- 概要
- 主要業界動向
第5章 世界のリキッドバイオプシー市場
- 市場概要
- 市場実績
- COVID-19の影響
- 市場予測
第6章 市場内訳：製品・サービス別
- キットと試薬
- 市場動向
- 市場予測
- プラットフォームと機器
- 市場動向
- 市場予測
- サービス
- 市場動向
- 市場予測
第7章 市場内訳：循環バイオマーカー
- 循環腫瘍細胞
- 市場動向
- 市場予測
- 細胞外小胞
- 市場動向
- 市場予測
- 循環腫瘍DNA
- 市場動向
- 市場予測
- その他
- 市場動向
- 市場予測
第8章 市場内訳：がんタイプ別
- 肺がん
- 市場動向
- 市場予測
- 乳がん
- 市場動向
- 市場予測
- 大腸がん
- 市場動向
- 市場予測
- 前立腺がん
- 市場動向
- 市場予測
- 肝臓がん
- 市場動向
- 市場予測
- その他
- 市場動向
- 市場予測
第9章 市場内訳：エンドユーザー別
- 病院と研究所
- 市場動向
- 市場予測
- 学術研究センター
- 市場動向
- 市場予測
- その他
- 市場動向
- 市場予測
第10章 市場内訳：地域別
- 北米
- 米国
- カナダ
- アジア太平洋
- 中国
- 日本
- インド
- 韓国
- オーストラリア
- インドネシア
- その他
- 欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- ロシア
- その他
- ラテンアメリカ
- ブラジル
- メキシコ
- その他
- 中東・アフリカ
- 市場動向
- 市場内訳：国別
- 市場予測
第11章 SWOT分析
- 概要
- 強み
- 弱み
- 機会
- 脅威
第12章 バリューチェーン分析
第13章 ポーターのファイブフォース分析
- 概要
- 買い手の交渉力
- 供給企業の交渉力
- 競合の程度
- 新規参入業者の脅威
- 代替品の脅威
第14章 価格分析
第15章 競合情勢
- 市場構造
- 主要企業
- 主要企業のプロファイル
- ANGLE plc
- Biocept Inc.
- Bio-Rad Laboratories Inc
- Epigenomics AG
- Exact Sciences Corporation
- F. Hoffmann-La Roche AG
- Guardant Health Inc.
- Illumina Inc.
- MDxHealth SA
- Menarini Silicon Biosystems
- QIAGEN N.V.
- Thermo Fisher Scientific Inc.
List of Figures
- Figure 1: Global: Liquid Biopsy Market: Major Drivers and Challenges
- Figure 2: Global: Liquid Biopsy Market: Sales Value (in Billion US$), 2018-2023
- Figure 3: Global: Liquid Biopsy Market Forecast: Sales Value (in Billion US$), 2024-2032
- Figure 4: Global: Liquid Biopsy Market: Breakup by Product and Service (in %), 2023
- Figure 5: Global: Liquid Biopsy Market: Breakup by Circulating Biomarker (in %), 2023
- Figure 6: Global: Liquid Biopsy Market: Breakup by Cancer Type (in %), 2023
- Figure 7: Global: Liquid Biopsy Market: Breakup by End User (in %), 2023
- Figure 8: Global: Liquid Biopsy Market: Breakup by Region (in %), 2023
- Figure 9: Global: Liquid Biopsy (Kits and Reagents) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 10: Global: Liquid Biopsy (Kits and Reagents) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 11: Global: Liquid Biopsy (Platforms and Instruments) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 12: Global: Liquid Biopsy (Platforms and Instruments) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 13: Global: Liquid Biopsy (Services) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 14: Global: Liquid Biopsy (Services) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 15: Global: Liquid Biopsy (Circulating Tumor Cells) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 16: Global: Liquid Biopsy (Circulating Tumor Cells) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 17: Global: Liquid Biopsy (Extracellular Vesicles) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 18: Global: Liquid Biopsy (Extracellular Vesicles) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 19: Global: Liquid Biopsy (Circulating Tumor DNA) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 20: Global: Liquid Biopsy (Circulating Tumor DNA) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 21: Global: Liquid Biopsy (Other Circulating Biomarkers) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 22: Global: Liquid Biopsy (Other Circulating Biomarkers) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 23: Global: Liquid Biopsy (Lung Cancer) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 24: Global: Liquid Biopsy (Lung Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 25: Global: Liquid Biopsy (Breast Cancer) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 26: Global: Liquid Biopsy (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 27: Global: Liquid Biopsy (Colorectal Cancer) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 28: Global: Liquid Biopsy (Colorectal Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 29: Global: Liquid Biopsy (Prostate Cancer) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 30: Global: Liquid Biopsy (Prostate Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 31: Global: Liquid Biopsy (Liver Cancer) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 32: Global: Liquid Biopsy (Liver Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 33: Global: Liquid Biopsy (Other Cancer Types) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 34: Global: Liquid Biopsy (Other Cancer Types) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 35: Global: Liquid Biopsy (Hospitals and Laboratories) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 36: Global: Liquid Biopsy (Hospitals and Laboratories) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 37: Global: Liquid Biopsy (Academic and Research Centers) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 38: Global: Liquid Biopsy (Academic and Research Centers) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 39: Global: Liquid Biopsy (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
- Figure 40: Global: Liquid Biopsy (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 41: North America: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 42: North America: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 43: United States: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 44: United States: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 45: Canada: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 46: Canada: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 47: Asia-Pacific: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 48: Asia-Pacific: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 49: China: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 50: China: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 51: Japan: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 52: Japan: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 53: India: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 54: India: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 55: South Korea: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 56: South Korea: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 57: Australia: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 58: Australia: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 59: Indonesia: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 60: Indonesia: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 61: Others: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 62: Others: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 63: Europe: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 64: Europe: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 65: Germany: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 66: Germany: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 67: France: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 68: France: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 69: United Kingdom: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 70: United Kingdom: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 71: Italy: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 72: Italy: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 73: Spain: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 74: Spain: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 75: Russia: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 76: Russia: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 77: Others: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 78: Others: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 79: Latin America: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 80: Latin America: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 81: Brazil: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 82: Brazil: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 83: Mexico: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 84: Mexico: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 85: Others: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 86: Others: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 87: Middle East and Africa: Liquid Biopsy Market: Sales Value (in Million US$), 2018 & 2023
- Figure 88: Middle East and Africa: Liquid Biopsy Market: Breakup by Country (in %), 2023
- Figure 89: Middle East and Africa: Liquid Biopsy Market Forecast: Sales Value (in Million US$), 2024-2032
- Figure 90: Global: Liquid Biopsy Industry: SWOT Analysis
- Figure 91: Global: Liquid Biopsy Industry: Value Chain Analysis
- Figure 92: Global: Liquid Biopsy Industry: Porter's Five Forces Analysis
List of Tables
- Table 1: Global: Liquid Biopsy Market: Key Industry Highlights, 2023 and 2032
- Table 2: Global: Liquid Biopsy Market Forecast: Breakup by Product and Service (in Million US$), 2024-2032
- Table 3: Global: Liquid Biopsy Market Forecast: Breakup by Circulating Biomarker (in Million US$), 2024-2032
- Table 4: Global: Liquid Biopsy Market Forecast: Breakup by Cancer Type (in Million US$), 2024-2032
- Table 5: Global: Liquid Biopsy Market Forecast: Breakup by End User (in Million US$), 2024-2032
- Table 6: Global: Liquid Biopsy Market Forecast: Breakup by Region (in Million US$), 2024-2032
- Table 7: Global: Liquid Biopsy Market: Competitive Structure
- Table 8: Global: Liquid Biopsy Market: Key Players
The global liquid biopsy market size reached US$ 2.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.5 Billion by 2032, exhibiting a growth rate (CAGR) of 13.5% during 2024-2032. The increasing prevalence of cancer, the rising demand for personalized medicine and treatments, and the development of automated liquid biopsy platforms, represent some of the key factors driving the liquid biopsy market growth.
Liquid Biopsy Market Analysis:
Major Market Drivers: The rising prevalence of cancer owing to changing lifestyle patterns, especially among working professionals, along with the introduction of next-generation sequencing is propelling the market growth. Liquid biopsies enable the detection of cancer-related biomarkers, such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), and exosomes, in bodily fluids like blood or urine. Early detection is crucial for effective treatment and improved patient outcomes, thereby driving the market growth.
Key Market Trends: Technological advancements, expanding clinical applications, a shift towards multi-analyte approaches, rising focus on early detection and screening, and elevating adoption of liquid biopsies in clinical trials are some of the key factors that are expected to stimulate the market growth in the coming years. Moreover, continuous innovation in sequencing technologies, microfluidics, and bioinformatics is enhancing the sensitivity, specificity, and scalability of liquid biopsy assays, thereby further bolstering the liquid biopsy market revenue.
Geographical Landscape: According to the report, North America accounted for the largest market share. Cancer remains a major health concern in North America, with a significant portion of the population being diagnosed with various types of cancer each year. The high incidence rates drive the demand for innovative diagnostic tools like liquid biopsies that offer non-invasive and accurate methods for cancer detection and monitoring. This is further positively impacting the liquid biopsy market demand.
Competitive Landscape: Some of the leading liquid biopsy market companies are ANGLE plc, Biocept Inc., Bio-Rad Laboratories Inc, Epigenomics AG, Exact Sciences Corporation, F. Hoffmann-La Roche AG, Guardant Health Inc., Illumina Inc., MDxHealth SA, Menarini Silicon Biosystems, QIAGEN N.V., and Thermo Fisher Scientific Inc., among many others.
Challenges and Opportunities: Standardization and validation of assays, clinical validation and evidence generation, and cost consideration and reimbursement are some of the key challenges that the market is currently facing. However, liquid biopsies can be integrated with digital health technologies, such as artificial intelligence (AI) and machine learning, to enhance data analysis, interpretation, and clinical decision-making. This represents key opportunities for the manufacturers.
Liquid Biopsy Market Trends:
Rising Prevalence of Cancer
With cancer rates on the rise globally, there's a growing emphasis on early detection and monitoring of the disease. For instance, according to WHO, in 2022, there were expected to be 20 million new cancer diagnoses and 9.7 million fatalities. The expected number of people who survived five years after a cancer diagnosis was 53.5 million. Cancer affects around one in every five persons in their lifetime. Over 35 million more cancer cases are expected in 2050, up 77% over the estimated 20 million in 2022. Liquid biopsies offer a non-invasive method to detect circulating tumor biomarkers, such as circulating tumor cells (CTCs) and cell-free DNA (cfDNA), in bodily fluids like blood or urine. These biomarkers can provide valuable insights into the presence, progression, and genetic profile of cancer, enabling clinicians to diagnose cancer at earlier stages and monitor disease progression more effectively. For instance, at the 2023 American Association of Cancer Research Annual Meeting, researchers presented a report on a liquid biopsy multicancer early detection test that analyzes DNA methylation using an innovative platform. While conventional tests need chemical treatment of DNA before sequencing, the novel approach captures methylated cfDNA molecules without any chemical or enzymatic treatment. The scientists conducted a retrospective analysis to examine the ability of the platform to detect 12 cancer types in a sample of around 4,000 people, including recently diagnosed, treatment-naive cancer patients, and age- and gender-matched controls. Approximately half of the cancer cases were in the early stages. In addition, in 2020, a team of researchers from the University of Pennsylvania released a paper in Clinical Cancer Research demonstrating that their liquid biopsy was 92% accurate in diagnosing early pancreatic cancer. These factors are further positively impacting the liquid biopsy market forecast.
Rising Demand for Non-Invasive Pre-Natal Tests (NIPT)
Traditional prenatal testing methods, such as amniocentesis and chorionic villus sampling (CVS), carry a small risk of complications, including miscarriage. NIPT, which involves analyzing cell-free fetal DNA (cffDNA) circulating in the mother's blood, offers a non-invasive alternative for prenatal screening. For instance, according to the National Library of Medicine, amniocentesis can be performed anywhere from 15 weeks of gestation to birth, with a 0.13% chance of loss in singletons in expert hands. In line with this, the risk of getting amniocentesis after 15 weeks of pregnancy is estimated to be 1 in 100. This non-invasive approach is preferred by many expectant parents due to its safety and reduced risk of procedure-related complications. Moreover, NIPT has demonstrated high accuracy in detecting common fetal chromosomal abnormalities, such as trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). Also, liquid biopsy based NIPT assays can detect fetal genetic abnormalities with high sensitivity and specificity, providing expectant parents with reliable information about their baby's health status. For instance, in November 2023, Yourgene Health, a subsidiary of Novacyt collaborated with Laboriad to introduce the first non-invasive prenatal testing (NIPT) platform in Morocco. Besides this, NIPT can be performed as early as 9-10 weeks into pregnancy, providing early insights into fetal genetic health. Early detection of chromosomal abnormalities allows expectant parents to make informed decisions about their pregnancy and consider additional diagnostic testing or preparation for the birth of a child with special needs. Furthermore, NIPT can be performed as early as 9-10 weeks into pregnancy, providing early insights into fetal genetic health. Early detection of chromosomal abnormalities allows expectant parents to make informed decisions about their pregnancy and consider additional diagnostic testing or preparation for the birth of a child with special needs. For instance, according to an article published by Cleveland Clinic, NIPT testing can be performed from as early as ten weeks of pregnancy until delivery. These factors are further positively influencing the liquid biopsy market's recent prices.
Rising R&D Activities and Clinical Trials
The rising technological advancements in liquid biopsies are escalating the frequency of cancer screening, drug trial optimization, and therapeutic selection. Various government agencies and companies are focusing on investment in research and development to conduct clinical studies on liquid biopsy. For instance, in June 2023, Anzu Partners led a US$15 Million Series A investment round for Codetta Biosciences. Genoa Ventures and VC23 LLC also contributed to the funding. With the funding, Codetta plans to rapidly expand its team in R&D, engineering, marketing, and business administration as well as quicken the development of its multi-omic dsPCR platform for liquid biopsy. Moreover, clinical trials serve as platforms for evaluating the performance of novel liquid biopsy technologies and platforms. Investment in research and development enables the development of next-generation sequencing (NGS) platforms, digital PCR systems, and other innovative technologies that enhance the sensitivity, specificity, and scalability of liquid biopsy assays. Clinical trials provide opportunities to validate these advancements in real-world clinical settings, paving the way for their commercialization and widespread adoption. For instance, in April 2024, NewBiologix SA, a technology innovation company focused on addressing gene therapy manufacturing gaps, launched its next-generation sequencing (NGS) and optical mapping platform, a novel suite of technologies that will provide comprehensive genomic analysis services to the biopharmaceutical industry. These factors are further contributing to the liquid biopsy market share.
Liquid Biopsy Industry Segmentation:
MARC Group provides an analysis of the key trends in each sub-segment of the global liquid biopsy market report, along with forecasts at the global, regional, and country levels from 2024-2032. Our report has categorized the market based on product and service, circulating biomarker, cancer type, and end user.
Breakup by Product and Service:
Kits and Reagents
Platforms and Instruments
Services
Kits and reagents assist dominates the market
The report has provided a detailed breakup and analysis of the liquid biopsy market based on the product and service. This includes kits and reagents, platforms and instruments and services. According to the report, kits and reagents represented the largest segment.
According to the liquid biopsy market outlook, the growth of kits and reagents segment is driven by the surging demand for liquid biopsy tests, especially for cancer diagnostics. These kits are used to isolate cell-free DNA from plasma or serum samples. They often utilize methods like spin column-based purification, magnetic bead-based purification, or precipitation-based methods. Moreover, rising research and development activities by the key players for the development of advanced kits are proliferating the segment's growth. For instance, in September 2023, Pillar Biosciences, Inc., Decision Medicine company, launched oncoReveal Core LBx, a research-use-only (RUO) next-generation sequencing (NGS) kit designed to enable laboratories with a solution for liquid biopsy-based pan-cancer tumor profiling.
Breakup by Circulating Biomarker:
Circulating Tumor Cells
Extracellular Vesicles
Circulating Tumor DNA
Others
Circulating tumor cells hold the largest share in the market
A detailed breakup and analysis of the liquid biopsy market based on the circulating biomarker has also been provided in the report. This includes circulating tumor cells, extracellular vesicles, circulating tumor DNA and others. According to the liquid biopsy market report, circulating tumor cells accounted for the largest market share.
According to the liquid biopsy market overview, the surging demand for Circulating Tumor Cells (CTC) is attributed to its wide range of applications in biomarkers such as gene expressions, protein expressions, and DNA mutations. Moreover, the clinical utility of CTC analysis in cancer diagnosis, prognosis, and treatment monitoring is increasingly recognized. As more clinical studies demonstrate the prognostic value of CTC enumeration, characterization, and genomic profiling in various cancer types, there is a growing demand for CTC-based tests in routine clinical practice. For instance, in September 2023, nRichDX introduced a novel RUO-labeled CTC enrichment kit that isolates Circulating Tumor Cells (CTCs) from up to 40mL of whole blood samples, assisting researchers in liquid biopsy assay research and development.
Breakup by Cancer Type:
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Liver Cancer
Others
Lung cancer accounts for the majority of the market share
The report has provided a detailed breakup and analysis of the liquid biopsy market based on the cancer type. This includes lung cancer, breast cancer, colorectal cancer, prostate cancer, liver cancer and others. According to the report, lung cancer represented the largest segment.
Liquid biopsy offers a non-invasive method for detecting and monitoring lung cancer compared to traditional tissue biopsies. Sampling blood for circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), or exosomes is less invasive and can be performed more frequently, allowing for real-time monitoring of disease progression and treatment response. Moreover, it enables the detection of lung cancer at early stages when tumors are smaller and more amenable to curative treatments. Additionally, it facilitates longitudinal monitoring of treatment response and disease recurrence, leading to timely adjustments in treatment strategies. For instance, in April 2024, researchers at The Royal Marsden and Guardant Health collaborated to develop a new liquid biopsy test that would assist thousands of lung cancer patients. Marsden360, a cutting-edge circulating tumor DNA (ctDNA) test, is expected to accelerate and personalize treatment for this patient population.
Breakup by End User:
Hospitals and Laboratories
Academic and Research Centers
Others
Hospitals and laboratories hold the largest share in the market
A detailed breakup and analysis of the liquid biopsy market based on the end user has also been provided in the report. This includes hospitals and laboratories, academic and research centers and others. According to the report, hospitals and laboratories accounted for the largest market share.
The growing demand for liquid biopsies in hospitals is mainly driven by the surging adoption of liquid biopsy tests for cancer diagnosis. Additionally, as the clinical utility of liquid biopsy in cancer management becomes increasingly recognized, there is a growing demand from hospitals and laboratories for tests that utilize liquid biopsy techniques. Liquid biopsy offers non-invasive methods for detecting and monitoring cancer, providing valuable information for diagnosis, prognosis, treatment selection, and monitoring of treatment response. For instance, in May 2024, Syndicate Bio, a Nigeria-based biotechnology lab, collaborated with SophiaGenetics, a cloud-native software corporation specialized in data-driven medicine, to provide extensive genomic profiling and liquid biopsy services.
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance in the market
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Latin America (Brazil, Mexico and others) and the Middle East and Africa. According to the report, North America was the largest market for liquid biopsy.
According to the liquid biopsy market statistics, some of the factors driving the North America liquid biopsy market included continual technological advancements, ongoing improvements in the healthcare industry, extensive research and development (R&D) activities conducted by key players, etc. Moreover, cancer remains a major health concern in North America, and the incidence rates continue to rise. Liquid biopsies offer a non-invasive method for detecting and monitoring cancer, which is particularly beneficial for early detection and personalized treatment strategies. Continuous advancements in technologies such as next-generation sequencing (NGS), digital PCR, and microfluidics have enhanced the sensitivity, accuracy, and reliability of liquid biopsy tests. These technological improvements have expanded the applications of liquid biopsies across various cancer types and stages. For instance, in April 2023, Quest Diagnostics, a diagnostic information services provider headquartered in U.S., acquired Haystack Oncology, an early-stage oncology company focused on minimal residual disease (MRD), the fastest-growing category of liquid biopsy testing to aid in the early, accurate detection of residual or recurring cancer and better inform therapy decisions.
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global liquid biopsy market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include:
ANGLE plc
Biocept Inc.
Bio-Rad Laboratories Inc
Epigenomics AG
Exact Sciences Corporation
F. Hoffmann-La Roche AG
Guardant Health Inc.
Illumina Inc.
MDxHealth SA
Menarini Silicon Biosystems
QIAGEN N.V.
Thermo Fisher Scientific Inc.
(Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.)
Liquid Biopsy Market Recent Developments:
May 2024: VESICA HEALTH, INC., a leading multi-omics liquid biopsy company, launched its laboratory developed AssureMDx test to improve the management of hematuria patients and the early detection of bladder cancer.
April 2024: SOPHiA GENETICS, a cloud-native software firm in healthcare and a leader in data-driven medicine, announced that Nigeria-based Syndicate Bio signed on to adopt MSK-ACCESS powered by SOPHiA DDM.
April 2024: City of Hope, one of the largest cancer research and treatment organizations in the United States, collaborated with DELFI Diagnostics, Inc., a developer of accessible blood-based tests that deliver a new way to enhance cancer detection, to utilize DELFI's FirstLook Lung, a blood-based lung cancer liquid biopsy screening test, to improve screening rates in underserved communities in Los Angeles County.
Key Questions Answered in This Report:
- How has the global liquid biopsy market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global liquid biopsy market?
- What is the impact of each driver, restraint, and opportunity on the global liquid biopsy market?
- What are the key regional markets?
- Which countries represent the most attractive liquid biopsy market?
- What is the breakup of the market based on the product and service?
- Which is the most attractive product and service in the liquid biopsy market?
- What is the breakup of the market based on the circulating biomarker?
- Which is the most attractive circulating biomarker in the liquid biopsy market?
- What is the breakup of the market based on cancer type?
- Which is the most attractive cancer type in the liquid biopsy market?
- What is the breakup of the market based on end use?
- Which is the most attractive end use in the liquid biopsy market?
- What is the competitive structure of the global liquid biopsy market?
- Who are the key players/companies in the global liquid biopsy market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Liquid Biopsy Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product and Service
- 6.1 Kits and Reagents
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Platforms and Instruments
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Services
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
7 Market Breakup by Circulating Biomarker
- 7.1 Circulating Tumor Cells
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Extracellular Vesicles
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Circulating Tumor DNA
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Others
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
8 Market Breakup by Cancer Type
- 8.1 Lung Cancer
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Breast Cancer
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Colorectal Cancer
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Prostate Cancer
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Liver Cancer
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
- 8.6 Others
- 8.6.1 Market Trends
- 8.6.2 Market Forecast
9 Market Breakup by End User
- 9.1 Hospitals and Laboratories
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Academic and Research Centers
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.1.1 United States
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.2.1 China
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.3.1 Germany
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.4.1 Brazil
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 ANGLE plc
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.2 Biocept Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.3 Bio-Rad Laboratories Inc
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 Epigenomics AG
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.5 Exact Sciences Corporation
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 F. Hoffmann-La Roche AG
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 SWOT Analysis
- 15.3.7 Guardant Health Inc.
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.8 Illumina Inc.
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 MDxHealth SA
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.10 Menarini Silicon Biosystems
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.11 QIAGEN N.V.
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.11.4 SWOT Analysis
- 15.3.12 Thermo Fisher Scientific Inc.
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
- 15.3.12.3 Financials
- 15.3.12.4 SWOT Analysis
- 15.3.1 ANGLE plc
